2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 565

Fetuin A: A New Biomarker Related with Syndesmophytes in Patients with Ankylosing Spondylitis
Abstract Number: 1188

Fibrinogen Induced Inhibition of Osteoclastogenesis Is Reversed by Citrullination of Fibrinogen by Peptidylarginine Deiminase
Abstract Number: 1860

Fibromyalgia and the Disease and Statistical Manual Classification As a Somatic Symptom Disorder
Abstract Number: 2394

Fibromyalgia in Behçet’s Disease Is Associated with Disease Activity
Abstract Number: 1884

Fibromyalgia Patients Who Meet the ACR 1990 Criteria Have More Severe Disease
Abstract Number: 1566

Fibromyalgia’s Impact On Relationships
Abstract Number: 10

Fibronectin Fragment Induces Procatabolic Effects Through TLR-2 Signaling Pathway in Human Articular Chondrocytes
Abstract Number: 1870

Financial Conflicts of Interest and Industry Sponsorship Are Associated with Positive Outcomes in Fibromyalgia Randomized Controlled Trials
Abstract Number: 1190

Fine Specificity of Anti-Citrullinated Peptide Antibodies Discloses a Heterogeneous Antibody Population in Rheumatoid Arthritis (RA)
Abstract Number: 2539

Fine-Specificity of Anti-Citrullinated Peptide Auto-Antibodies: Associations with Cardiac Structure and Function in Rheumatoid Arthritis
Abstract Number: 709

Fingertip Skin Hardness in Limited Scleroderma: Durometry versus Manual Assessment
Abstract Number: 1279

First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis
Abstract Number: L11

First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial
Abstract Number: 414

First-Degree Relatives without Rheumatoid Arthritis Exhibit Reactivity to Multiple Anti-Citrullinated Protein Antibodies in Association with Rheumatoid Arthritis-Related Clinical Characteristics: Studies of the Etiology of Rheumatoid Arthritis
Abstract Number: 453

Fish Oil in Rheumatoid Arthritis: A Randomised, Double Blind Trial Comparing High Dose with Low Dose

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].